Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 3/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258477 | 1.00 | NOD1 (0.49) | NOD1DPP8DPP7GHSRERAP2 | |
| SCHEMBL1258476 | 1.00 | NOD1 (0.49) | NOD1DPP8DPP7GHSRERAP2 | |
| SCHEMBL1257530 | 0.78 | NOS2 (0.35) | NOD1DPP8DPP7ERAP2ERAP1 | |
| SCHEMBL1257531 | 0.78 | NOS2 (0.35) | NOD1DPP8DPP7ERAP2ERAP1 | |
| SCHEMBL1259321 | 0.76 | KMT2A (0.43) | ERAP2ERAP1LNPEPCA1 | |
| SCHEMBL1259391 | 0.76 | KMT2A (0.43) | ERAP2ERAP1LNPEPCA1 | |
| SCHEMBL1259326 | 0.76 | KMT2A (0.43) | ERAP2ERAP1LNPEPCA1 | |
| SCHEMBL6670962 | 0.76 | GABRP (0.41) | — | |
| SCHEMBL20653679 | 0.73 | NOD1 (0.55) | NOD1DPP8DPP7GHSRERAP2 | |
| SCHEMBL31686179 | 0.73 | NOD1 (0.55) | NOD1DPP8DPP7GHSRERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252940-B2 | 5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection | UNIVERSITY OF WASHINGTON (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110039849-A1 | 5-SUBSTITUTED-2-IMINO-THIAZOLIDINONE COMPOUNDS AND THEIR USE AS INHIBITORS OF BACTERIAL INFECTION | UNIVERSITY OF WASHINGTON (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009137133-A2 | 5-SUBSTITUTED-2-IMINO-THIAZOLIDINONE COMPOUNDS AND THEIR USE AS INHIBITORS OF BACTERIAL INFECTION | UNIVERSITY OF WASHINGTON (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039849-A1 | 5-SUBSTITUTED-2-IMINO-THIAZOLIDINONE COMPOUNDS AND THEIR USE AS INHIBITORS OF BACTERIAL INFECTION | IRF3, GDI2, TLR5 | NOD1 14/4885DPP8 546/4885DPP7 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.